Buffington Mohr McNeal decreased its holdings in UnitedHealth Group Inc (NYSE:UNH) by 32.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,135 shares of the healthcare conglomerate’s stock after selling 1,004 shares during the quarter. Buffington Mohr McNeal’s holdings in UnitedHealth Group were worth $454,000 at the end of the most recent reporting period.
Several other institutional investors have also modified their holdings of the stock. Longview Partners Guernsey LTD grew its stake in shares of UnitedHealth Group by 4.8% in the third quarter. Longview Partners Guernsey LTD now owns 4,724,845 shares of the healthcare conglomerate’s stock worth $925,361,000 after purchasing an additional 214,300 shares during the last quarter. Ironwood Investment Counsel LLC bought a new stake in shares of UnitedHealth Group in the third quarter worth $328,000. Heritage Investors Management Corp grew its stake in shares of UnitedHealth Group by 8.5% in the third quarter. Heritage Investors Management Corp now owns 21,185 shares of the healthcare conglomerate’s stock worth $4,149,000 after purchasing an additional 1,668 shares during the last quarter. Bainco International Investors grew its stake in shares of UnitedHealth Group by 5.4% in the third quarter. Bainco International Investors now owns 82,676 shares of the healthcare conglomerate’s stock worth $16,192,000 after purchasing an additional 4,202 shares during the last quarter. Finally, Cable Hill Partners LLC grew its stake in shares of UnitedHealth Group by 337.4% in the third quarter. Cable Hill Partners LLC now owns 1,894 shares of the healthcare conglomerate’s stock worth $371,000 after purchasing an additional 1,461 shares during the last quarter. 86.01% of the stock is currently owned by institutional investors.
In related news, CEO Larry C. Renfro sold 22,598 shares of the company’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $221.75, for a total value of $5,011,106.50. Following the sale, the chief executive officer now owns 195,314 shares in the company, valued at approximately $43,310,879.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Gail R. Wilensky sold 5,600 shares of the company’s stock in a transaction dated Wednesday, November 29th. The stock was sold at an average price of $223.31, for a total transaction of $1,250,536.00. Following the completion of the sale, the director now owns 61,137 shares in the company, valued at approximately $13,652,503.47. The disclosure for this sale can be found here. Insiders sold a total of 34,630 shares of company stock worth $7,669,416 in the last 90 days. 0.89% of the stock is currently owned by company insiders.
UnitedHealth Group Inc (UNH) opened at $228.64 on Friday. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 0.52. UnitedHealth Group Inc has a fifty-two week low of $156.09 and a fifty-two week high of $231.77. The firm has a market cap of $221,060.00, a PE ratio of 25.98, a PEG ratio of 1.57 and a beta of 0.66.
UnitedHealth Group (NYSE:UNH) last posted its earnings results on Tuesday, October 17th. The healthcare conglomerate reported $2.66 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.57 by $0.09. UnitedHealth Group had a net margin of 4.50% and a return on equity of 21.52%. The company had revenue of $50.32 billion for the quarter, compared to analyst estimates of $50.38 billion. During the same quarter in the prior year, the business posted $2.17 EPS. The firm’s revenue was up 8.7% compared to the same quarter last year. sell-side analysts forecast that UnitedHealth Group Inc will post 9.99 EPS for the current fiscal year.
UNH has been the topic of several recent analyst reports. Zacks Investment Research upgraded shares of UnitedHealth Group from a “hold” rating to a “buy” rating and set a $219.00 target price on the stock in a report on Thursday, September 21st. ValuEngine lowered shares of UnitedHealth Group from a “buy” rating to a “hold” rating in a report on Thursday, October 5th. Sanford C. Bernstein restated an “outperform” rating and issued a $210.00 target price on shares of UnitedHealth Group in a report on Tuesday, October 10th. Jefferies Group boosted their target price on shares of UnitedHealth Group from $215.00 to $225.00 and gave the company a “buy” rating in a report on Friday, October 13th. Finally, BMO Capital Markets initiated coverage on shares of UnitedHealth Group in a report on Monday, October 16th. They issued an “outperform” rating and a $250.00 target price on the stock. Three research analysts have rated the stock with a hold rating and twenty-five have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $229.54.
UnitedHealth Group Company Profile
UnitedHealth Group Incorporated is a health and well-being company. The Company operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. It conducts its operations through two business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.
Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.